Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05964751
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-07-28
First Post:
2023-07-18
Brief Title:
the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Systemic lupus erythematosus SLE is a heterogeneous autoimmune disease that involve s many different organs and display a variable clinical course The prevalence of SLE varies across gender raceethnicity and geographic regions SLE demonstrates a striking female predominance with a peak incidence of disease during the reproductive years In adults the female to male ratio is 10-151
Clinical features in individual patients can be quite variable and range from mild joint and skin involvement to severe life-threatening internal organ disease Constitutional symptoms rash mucosal ulcers inflammatory polyarthritis photosensitivity and serositis are the most common clinical features of the disease
Major organ affection in SLE includes Neuropsychiatric involvement cognitive impairment depression psychosis seizures stroke demyelinating syndromes peripheral neuropathy etc and cardiopulmonary manifestations Lupus nephritis is the most common of the potentially life-threatening manifestations
Renal involvement is common in SLE and is a significant cause of morbidity and mortality It is estimated that as many as 90 of patients with SLE will have pathologic evidence of renal involvement on biopsy but clinically significant nephritis will develop in only 50
Lupus involvement in the kidney manifests as urinary findings proteinuria hematuria pathologic casts with or without a rise in serum creatinine The specific criteria listed for renal involvement are a urine protein 500 mgdL or red blood cell casts Lupus nephritis is often confirmed by kidney biopsy with the results showing one or more of the classes of lupus nephritis
The metabolic syndrome is a prevalent disorder which is defined by the presence of central obesity dyslipidemia hypertension and disturbed glucose metabolism It is known that Metabolic syndrome predisposes to cardiovascular disease CVD and consequently to a rise in CVD morbidity and mortality This syndrome plays a major role in the complex network of systemic pro-inflammatory and prothrombotic states involved in the development of CVD
Compared with patients without Metabolic syndrome SLE patients from the multinational multiethnic Systemic Lupus Erythematosus International Collaborating Clinics SLICC cohort with the diagnosis of Metabolic syndrome were older had a higher disease activity an increased number of recent disease flares and had accrued more organ damage Mok et al report that Metabolic syndrome is significantly associated with new organ damage vascular events and mortality in patients with SLE
Clinical features in individual patients can be quite variable and range from mild joint and skin involvement to severe life-threatening internal organ disease Constitutional symptoms rash mucosal ulcers inflammatory polyarthritis photosensitivity and serositis are the most common clinical features of the disease
Major organ affection in SLE includes Neuropsychiatric involvement cognitive impairment depression psychosis seizures stroke demyelinating syndromes peripheral neuropathy etc and cardiopulmonary manifestations Lupus nephritis is the most common of the potentially life-threatening manifestations
Renal involvement is common in SLE and is a significant cause of morbidity and mortality It is estimated that as many as 90 of patients with SLE will have pathologic evidence of renal involvement on biopsy but clinically significant nephritis will develop in only 50
Lupus involvement in the kidney manifests as urinary findings proteinuria hematuria pathologic casts with or without a rise in serum creatinine The specific criteria listed for renal involvement are a urine protein 500 mgdL or red blood cell casts Lupus nephritis is often confirmed by kidney biopsy with the results showing one or more of the classes of lupus nephritis
The metabolic syndrome is a prevalent disorder which is defined by the presence of central obesity dyslipidemia hypertension and disturbed glucose metabolism It is known that Metabolic syndrome predisposes to cardiovascular disease CVD and consequently to a rise in CVD morbidity and mortality This syndrome plays a major role in the complex network of systemic pro-inflammatory and prothrombotic states involved in the development of CVD
Compared with patients without Metabolic syndrome SLE patients from the multinational multiethnic Systemic Lupus Erythematosus International Collaborating Clinics SLICC cohort with the diagnosis of Metabolic syndrome were older had a higher disease activity an increased number of recent disease flares and had accrued more organ damage Mok et al report that Metabolic syndrome is significantly associated with new organ damage vascular events and mortality in patients with SLE
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None